NG-Panel (Next-Generation Sequencing) tests are targeted molecular diagnostic assays designed to analyze hundreds of genes associated with a specific organ system or disease group (e.g., Neurology, Ophthalmology, Metabolic) simultaneously in a single workflow. Compared to single-gene testing, they offer significant time and cost efficiency while providing base-pair resolution to detect point mutations and micro-deletions/duplications missed by conventional cytogenetic methods (like Karyotyping).

Most panel tests require a single tube of peripheral blood (EDTA purple-top tube) or, in specific cases, a saliva/buccal swab sample. Because NG-Panel testing directly evaluates DNA sequences, fasting, diet, or current medications do not affect the results; samples can be collected at any time of day.

Including high-depth sequencing, bioinformatic processing, and multidisciplinary medical curation, panel test results are typically completed within 2 to 4 weeks and issued as a comprehensive clinical report. You can access your test results through our website.

Yes, absolutely. Many inherited metabolic, neurological, or developmental disorders follow an autosomal recessive inheritance pattern, where both parents are asymptomatic carriers and the condition manifests only when the child inherits two mutated alleles. Additionally, de novo mutations—new genetic changes that arise spontaneously during gametogenesis or early embryogenesis—frequently occur without any family history.

A VUS indicates that a genetic alteration was identified in a panel gene, but current global medical literature lacks sufficient evidence to definitively classify it as benign or disease-causing. In such scenarios, our clinical team may recommend parental testing (Trio analysis) or functional/phenotypic correlation to further clarify the variant's clinical relevance.

In many cases, yes. Identifying the underlying genetic cause allows for precision medicine strategies: metabolic panels can guide early nutritional or enzyme replacement therapies (ERT), while neurology and ophthalmology panels can determine eligibility for FDA-approved gene therapies (e.g., Luxturna, SMA gene replacement) or targeted clinical management protocols to slow disease progression.